Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for NeoGenomics Inc. (NEO:NASDAQ), powered by AI.
NeoGenomics Inc. is currently trading at $9.44. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for NeoGenomics Inc. on Alpha Lenz.
NeoGenomics Inc.'s P/E ratio is -15.2.
“ NeoGenomics Inc. trades at a P/E of -15.2 (undervalued) with modest ROE of -8.5%. 3Y revenue CAGR of 10.9% highlights clear growth momentum.”
Ask for details →NeoGenomics Inc. is a prominent player in the healthcare and pharmaceutical industry, specializing in cancer diagnostics and related genetic testing services. The company offers a comprehensive range of diagnostic services aimed at aiding in the precise determination of cancer-related conditions. These services include advanced pathology, genetic testing, and comprehensive genomic profiling, which play a crucial role in personalizing patient care by informing treatment strategies. NeoGenomics serves a broad client base including oncologists, pathologists, hospitals, academic institutions, and pharmaceutical companies engaged in the development of targeted therapies. Headquartered in Fort Myers, Florida, NeoGenomics is committed to providing leading-edge diagnostics that support the growing demand for personalized medicine. By emphasizing innovation and research, NeoGenomics continues to significantly impact the oncology market and contribute to advancements in cancer treatment and precision medicine.
“ NeoGenomics Inc. trades at a P/E of -15.2 (undervalued) with modest ROE of -8.5%. 3Y revenue CAGR of 10.9% highlights clear growth momentum.”
Ask for details →NeoGenomics Inc. (ticker: NEO) is a company listed on NASDAQ in the Healthcare sector (Diagnostics & Research). It has approximately 2,200 employees. Market cap is $1.2B.
The current price is $9.44 with a P/E ratio of -15.19x and P/B of 1.33x.
ROE is -8.54% and operating margin is -12.94%. Annual revenue is $661M.